1,364 results on '"Vranckx, Pascal"'
Search Results
2. One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease
3. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial
4. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
5. One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial
6. Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial
7. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
8. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
9. Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week
10. One- Versus Three-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease
11. Management of Bleeding and Hemolysis During Percutaneous Microaxial Flow Pump Support: A Practical Approach
12. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
13. Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis
14. Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial
15. Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR
16. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
17. Unveiling new horizons: revolutionary insights into acute myocarditis and optimal mechanical circulatory support timing
18. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents in patients with acute coronary syndrome: The ULTIMATE-DAPT trial
19. Acute cardiac and intensive care chronicles: navigating the intersection of cardiovascular health, recreational drug use, and beyond!
20. European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: A survey of the Association for Acute CardioVascular Care (ACVC) of the ESC and the European branch of the Extracorporeal Life Support Organization (EuroELSO)
21. Predicting medical usage rate at mass gathering events in Belgium: development and validation of a nonlinear multivariable regression model
22. Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks
23. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk
24. Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy
25. Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week
26. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
27. Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery
28. European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization.
29. Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure
30. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
31. March 2024 issue of the European Heart Journal Acute Cardiovascular Care
32. Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk
33. Acute cardiovascular and intensive care chronicles: ‘inception revealed—navigating the veno-arterial extracorporeal membrane oxygenation terrain and beyond’
34. Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines
35. As we reflect on the year 2023…….
36. Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis
37. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis
38. Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management
39. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes
40. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)
41. Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria
42. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
43. The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial
44. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS
45. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI
46. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study
47. Editors' perspective
48. One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: a Pre-Specified Analysis of the SWISS-APERO Randomized Clinical Trial
49. Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial
50. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.